CPI-17 (phospho Thr38) Rabbit Polyclonal Antibody

Description: A Rabbit Polyclonal antibody against CPI-17 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Description: A polyclonal antibody for detection of CPI-17 from Human, Mouse, Rat. This CPI-17 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human CPI-17 around the non-phosphorylation site of T38

Description: A polyclonal antibody for detection of CPI-17 from Human, Mouse, Rat. This CPI-17 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human CPI-17 around the non-phosphorylation site of T38

Description: A polyclonal antibody for detection of CPI-17 from Human, Mouse, Rat. This CPI-17 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human CPI-17 around the non-phosphorylation site of T38

Description: Rabbit polyclonal to Phospho-CPI-17 (T38).

Description: Rabbit polyclonal to CPI-17.

Description: A Rabbit Polyclonal antibody against Ets-1 (phospho Thr38) from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Description: A Rabbit Polyclonal antibody against Ets-1 (phospho Thr38) from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Description: A polyclonal antibody for detection of Ets-1 phospho Thr38) from Human, Mouse, Rat. This Ets-1 phospho Thr38) antibody is for WB , IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Ets-1 around the phosphorylation site of T38

Description: A polyclonal antibody for detection of Ets-1 phospho Thr38) from Human, Mouse, Rat. This Ets-1 phospho Thr38) antibody is for WB , IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Ets-1 around the phosphorylation site of T38

Description: A polyclonal antibody for detection of Ets-1 phospho Thr38) from Human, Mouse, Rat. This Ets-1 phospho Thr38) antibody is for WB , IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Ets-1 around the phosphorylation site of T38

Description: A polyclonal antibody against Phospho-Ets1 (Thr38). Recognizes Phospho-Ets1 (Thr38) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:1000, IHC:1:50-1:100, IF:1:100-1:200

Description: A polyclonal antibody against Phospho-Ets1 (Thr38). Recognizes Phospho-Ets1 (Thr38) from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:1000, IHC:1:50-1:100, IF:1:100-1:200

Description: Phospho-CPI17 alpha (Thr38) Antibody detects endogenous levels of CPI17 alpha only when phosphorylated at Threonine 38.

Description: Rabbit polyclonal ETS1 antibody (Thr38)

Description: A Monoclonal antibody against Human CPI-17 alpha (N-term). The antibodies are raised in Rabbit and are from clone E305. This antibody is applicable in WB and IHC

Description: A Rabbit Polyclonal antibody against HMG-17 (phospho Ser29) from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA

Description: A Rabbit Polyclonal antibody against HMG-17 (phospho Ser29) from Human/Mouse/Rat. This antibody is tested and validated for IHC, WB, ELISA

Description: A polyclonal antibody for detection of HMG-17 phospho Ser29) from Human, Mouse, Rat. This HMG-17 phospho Ser29) antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human HMG-17 around the phosphorylation site of S29

Description: A polyclonal antibody for detection of HMG-17 phospho Ser29) from Human, Mouse, Rat. This HMG-17 phospho Ser29) antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human HMG-17 around the phosphorylation site of S29

Description: A polyclonal antibody for detection of HMG-17 phospho Ser29) from Human, Mouse, Rat. This HMG-17 phospho Ser29) antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human HMG-17 around the phosphorylation site of S29

Description: Rabbit polyclonal CPI17 alpha antibody (Thr38)

Description: CPI-169 is a novel, small molecule and potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2) [1].CPI-169 has been found to be a potent EZH2 inhibitor with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2).

Description: CPI-169 is a novel, small molecule and potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2) [1].CPI-169 has been found to be a potent EZH2 inhibitor with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2).

Description: CPI-169 is a novel, small molecule and potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2) [1].CPI-169 has been found to be a potent EZH2 inhibitor with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2).

Description: CPI-169 is a novel, small molecule and potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2) [1].CPI-169 has been found to be a potent EZH2 inhibitor with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2).

Description: CPI-169 is a novel, small molecule and potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2) [1].CPI-169 has been found to be a potent EZH2 inhibitor with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2).

Description: CPI-1189 is a proapoptotic cytokine tumor necrosis factor (TNF) alpha inhibitor.AIDS dementia complex is characterized by increased gliosis, apoptosis, and oxidative stress in the CNS, as well as a compromised blood-brain barrier.

Description: CPI-1189 is a proapoptotic cytokine tumor necrosis factor (TNF) alpha inhibitor.AIDS dementia complex is characterized by increased gliosis, apoptosis, and oxidative stress in the CNS, as well as a compromised blood-brain barrier.

Description: CPI-203 is a potent, selectivie and competitive small molecule inhibitor of BET bromodomain with a mean GI50 value of 0.23?M in MCL cell lines [1].As an inhibitor of BET proteins, CPI-203 inhibits BRD4 in vitro and in cells.

Description: IC50: 0.03 and 11.0 ?M for CBP/EP300 and BRD4, respectively.CPI-637 is a CBP/EP300 bromodomain inhibitor.

Description: IC50: 0.03 and 11.0 ?M for CBP/EP300 and BRD4, respectively.CPI-637 is a CBP/EP300 bromodomain inhibitor.

Description: IC50: 10 nMCPI-455 is a KDM5 inhibitor.The KDM5 family of histone demethylases catalyzes the demethylation of histone H3 on lysine 4 (H3K4) and is required for the survival of drug-tolerant persister cancer cells (DTPs).

Description: IC50: 10 nMCPI-455 is a KDM5 inhibitor.The KDM5 family of histone demethylases catalyzes the demethylation of histone H3 on lysine 4 (H3K4) and is required for the survival of drug-tolerant persister cancer cells (DTPs).

Description: 0.002 ?M for biochemical IC50; 0.032 ?M for cellular EC50. CPI-1205 is an EZH2 inhibitor.Polycomb repressive complex 2 (PRC2) plays a key role in transcriptional silencing partially by installing methylation marks on lysine 27 of histone 3.

Description: 0.002 ?M for biochemical IC50; 0.032 ?M for cellular EC50. CPI-1205 is an EZH2 inhibitor.Polycomb repressive complex 2 (PRC2) plays a key role in transcriptional silencing partially by installing methylation marks on lysine 27 of histone 3.

Description: 0.002 ?M for biochemical IC50; 0.032 ?M for cellular EC50. CPI-1205 is an EZH2 inhibitor.Polycomb repressive complex 2 (PRC2) plays a key role in transcriptional silencing partially by installing methylation marks on lysine 27 of histone 3.

Description: CPI-613 is a first-in-class anti-cancer agent [1].CPI-613 is developed to target the pyruvate dehydrogenase complex which is a key mitochondrial enzyme of anaerobic glycolysis in tumor cells.

Description: CPI-613 is a first-in-class anti-cancer agent [1].CPI-613 is developed to target the pyruvate dehydrogenase complex which is a key mitochondrial enzyme of anaerobic glycolysis in tumor cells.

Description: CPI-613 is a first-in-class anti-cancer agent [1].CPI-613 is developed to target the pyruvate dehydrogenase complex which is a key mitochondrial enzyme of anaerobic glycolysis in tumor cells.

Description: CPI-613 is a first-in-class anti-cancer agent [1].CPI-613 is developed to target the pyruvate dehydrogenase complex which is a key mitochondrial enzyme of anaerobic glycolysis in tumor cells.

Description: CPI-613 is a first-in-class anti-cancer agent [1].CPI-613 is developed to target the pyruvate dehydrogenase complex which is a key mitochondrial enzyme of anaerobic glycolysis in tumor cells.